<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">32110228</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1662-680X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Season>Jan-Apr</Season>
            </PubDate>
          </JournalIssue>
          <Title>Case reports in neurology</Title>
          <ISOAbbreviation>Case Rep Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent.</ArticleTitle>
        <Pagination>
          <StartPage>50</StartPage>
          <EndPage>55</EndPage>
          <MedlinePgn>50-55</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000505232</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic neurological syndromes (PNS) associated with anti-CV2/CRMP5 antibodies are rare in the literature. Various clinical manifestations can occur including paraneoplastic limbic encephalitis (PLE). Thymoma is one of the rare causes that can be associated with this syndrome. It has not been reported in the literature in children or adolescents to the best of our knowledge. We report a case of PLE in a 19-year-old male patient secondary to thymoma that was diagnosed after 5 years of onset. Anti-CV2/CRMP5 antibodies were positive in the serum and became negative after thymectomy. Diagnosis of PNS should be evoked in cases with atypical neurological manifestation and can be confirmed by the presence of onconeuronal antibodies. We report the first pediatric PLE secondary to thymoma associated with anti-CV2/CRMP5 antibodies.</AbstractText>
          <CopyrightInformation>Copyright © 2020 by S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ibrahim Ismail</LastName>
            <ForeName>Ismail</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>K John</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ibrahim</LastName>
            <ForeName>Mohamed</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Hashel</LastName>
            <ForeName>Jasem Yousef</ForeName>
            <Initials>JY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Faculty of Medicine, Health Sciences Centre, Kuwait University, Kuwait City, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Case Rep Neurol</MedlineTA>
        <NlmUniqueID>101517693</NlmUniqueID>
        <ISSNLinking>1662-680X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CRMP5</Keyword>
        <Keyword MajorTopicYN="N">CV2</Keyword>
        <Keyword MajorTopicYN="N">Limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Onconeuronal antibodies</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic syndromes</Keyword>
        <Keyword MajorTopicYN="N">Thymoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32110228</ArticleId>
        <ArticleId IdType="pmc">PMC7036575</ArticleId>
        <ArticleId IdType="doi">10.1159/000505232</ArticleId>
        <ArticleId IdType="pii">crn-0012-0050</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008 Apr;7((4)):327–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist. 2006 Mar;11((3)):292–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16549814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007 May;2((1)):22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868710</ArticleId>
            <ArticleId IdType="pubmed">17480225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaf JH, Tamminga RY, Kamps WA. Paraneoplastic manifestations in children. Eur J Pediatr. 1994 Nov;153((11)):784–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7843190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123((Pt 7)):1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knudsen A, Bredholt G, Storstein A, Oltedal L, Davanger S, Krossnes B, et al.  Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol. 2007 Jul;149((1)):16–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1942032</ArticleId>
            <ArticleId IdType="pubmed">17403058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukada M, Watakabe I, Yuasa-Kawada J, Kawachi H, Kuroiwa A, Matsuda Y, et al.  Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J Biol Chem. 2000 Dec;275((48)):37957–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10956643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother. 2008 Feb;57((2)):227–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17657489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alavi S. Paraneoplastic neurologic syndromes in children: a review article. Iran J Child Neurol. 2013;7((3)):6–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3943073</ArticleId>
            <ArticleId IdType="pubmed">24665300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda S, Miyoshi S, Akashi A, Ohta M, Minami M, Okumura M, et al.  Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution. J Surg Oncol. 2003 May;83((1)):24–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12722093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009 Apr;80((4)):412–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2664637</ArticleId>
            <ArticleId IdType="pubmed">18931014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio-Agusti I, Salavert M, Bataller L. Limbic encephalitis and related cortical syndromes. Curr Treat Options Neurol. 2013 Apr;15((2)):169–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23250843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010 Sep;85((9)):838–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2931619</ArticleId>
            <ArticleId IdType="pubmed">20810794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007 Apr;78((4)):381–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2077770</ArticleId>
            <ArticleId IdType="pubmed">16980333</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">32110228</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1662-680X</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Season>Jan-Apr</Season>
            </PubDate>
          </JournalIssue>
          <Title>Case reports in neurology</Title>
          <ISOAbbreviation>Case Rep Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Paraneoplastic Limbic Encephalitis Associated with Anti-CV2/CRMP5 Antibodies Secondary to Thymoma in an Adolescent.</ArticleTitle>
        <Pagination>
          <StartPage>50</StartPage>
          <EndPage>55</EndPage>
          <MedlinePgn>50-55</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000505232</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic neurological syndromes (PNS) associated with anti-CV2/CRMP5 antibodies are rare in the literature. Various clinical manifestations can occur including paraneoplastic limbic encephalitis (PLE). Thymoma is one of the rare causes that can be associated with this syndrome. It has not been reported in the literature in children or adolescents to the best of our knowledge. We report a case of PLE in a 19-year-old male patient secondary to thymoma that was diagnosed after 5 years of onset. Anti-CV2/CRMP5 antibodies were positive in the serum and became negative after thymectomy. Diagnosis of PNS should be evoked in cases with atypical neurological manifestation and can be confirmed by the presence of onconeuronal antibodies. We report the first pediatric PLE secondary to thymoma associated with anti-CV2/CRMP5 antibodies.</AbstractText>
          <CopyrightInformation>Copyright © 2020 by S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ibrahim Ismail</LastName>
            <ForeName>Ismail</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>K John</LastName>
            <ForeName>John</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ibrahim</LastName>
            <ForeName>Mohamed</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Al-Hashel</LastName>
            <ForeName>Jasem Yousef</ForeName>
            <Initials>JY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Ibn Sina Hospital, Safat, Kuwait.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Faculty of Medicine, Health Sciences Centre, Kuwait University, Kuwait City, Kuwait.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>02</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Case Rep Neurol</MedlineTA>
        <NlmUniqueID>101517693</NlmUniqueID>
        <ISSNLinking>1662-680X</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">CRMP5</Keyword>
        <Keyword MajorTopicYN="N">CV2</Keyword>
        <Keyword MajorTopicYN="N">Limbic encephalitis</Keyword>
        <Keyword MajorTopicYN="N">Onconeuronal antibodies</Keyword>
        <Keyword MajorTopicYN="N">Paraneoplastic syndromes</Keyword>
        <Keyword MajorTopicYN="N">Thymoma</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32110228</ArticleId>
        <ArticleId IdType="pmc">PMC7036575</ArticleId>
        <ArticleId IdType="doi">10.1159/000505232</ArticleId>
        <ArticleId IdType="pii">crn-0012-0050</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008 Apr;7((4)):327–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2367117</ArticleId>
            <ArticleId IdType="pubmed">18339348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Beukelaar JW, Sillevis Smitt PA. Managing paraneoplastic neurological disorders. Oncologist. 2006 Mar;11((3)):292–305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16549814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007 May;2((1)):22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868710</ArticleId>
            <ArticleId IdType="pubmed">17480225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Graaf JH, Tamminga RY, Kamps WA. Paraneoplastic manifestations in children. Eur J Pediatr. 1994 Nov;153((11)):784–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7843190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000 Jul;123((Pt 7)):1481–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10869059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knudsen A, Bredholt G, Storstein A, Oltedal L, Davanger S, Krossnes B, et al.  Antibodies to CRMP3-4 associated with limbic encephalitis and thymoma. Clin Exp Immunol. 2007 Jul;149((1)):16–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1942032</ArticleId>
            <ArticleId IdType="pubmed">17403058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukada M, Watakabe I, Yuasa-Kawada J, Kawachi H, Kuroiwa A, Matsuda Y, et al.  Molecular characterization of CRMP5, a novel member of the collapsin response mediator protein family. J Biol Chem. 2000 Dec;275((48)):37957–65.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10956643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monstad SE, Drivsholm L, Skeie GO, Aarseth JH, Vedeler CA. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunol Immunother. 2008 Feb;57((2)):227–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17657489</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alavi S. Paraneoplastic neurologic syndromes in children: a review article. Iran J Child Neurol. 2013;7((3)):6–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3943073</ArticleId>
            <ArticleId IdType="pubmed">24665300</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeda S, Miyoshi S, Akashi A, Ohta M, Minami M, Okumura M, et al.  Clinical spectrum of primary mediastinal tumors: a comparison of adult and pediatric populations at a single Japanese institution. J Surg Oncol. 2003 May;83((1)):24–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12722093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al.  Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009 Apr;80((4)):412–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2664637</ArticleId>
            <ArticleId IdType="pubmed">18931014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rubio-Agusti I, Salavert M, Bataller L. Limbic encephalitis and related cortical syndromes. Curr Treat Options Neurol. 2013 Apr;15((2)):169–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23250843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010 Sep;85((9)):838–54.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2931619</ArticleId>
            <ArticleId IdType="pubmed">20810794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry. 2007 Apr;78((4)):381–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2077770</ArticleId>
            <ArticleId IdType="pubmed">16980333</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
